Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
81actual
Sites
33
Countries
Australia, France, Israel +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-02-23 | actual | When the study began enrolling |
| Primary completion | Feb 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-01-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumors Cancer
- Non Small Cell Lung Cancer (NSCLC)
Interventions
- Drug: ABBV-637
- Drug: Docetaxel
- Drug: Osimertinib
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Adverse Events (AEs)
measured Up to approximately 3 years
Percentage of Participants With Objective Response Rate (ORR) (Part 2 & 3)
measured Up to approximately 3 years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed